Navigation Links
Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

About Special Protocol Assessments

The Special Protocol Assessment (SPA) process is a procedure by which the FDA provides official evaluation and written guidance on the design and size of proposed protocols that are intended to form the basis for a new drug application.

Final marketing approval depends on the results of efficacy, the adverse event profile and an evaluation of the benefit/risk of treatment demonstrated in the Phase 3 trial. The SPA agreement may only be changed through a written agreement between the sponsor and the FDA, or if the FDA becomes aware of a substantial scientific issue essential to product efficacy or safety. For more information on Special Protocol Assessment, please visit: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080571.pdf

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK pathway, which are pathways associated with programmed cell death, cell growth, ce
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... N.C. , Aug. 28, 2015  Delays ... research projects can slow down the decision-making process, ... is, therefore, absolutely critical for biopharmaceutical companies to ... research approval process for quicker and more meaningful ... by Best Practices, LLC, nearly three-quarters of benchmarked ...
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Pranoprofen Market, 2010-2019" ... discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly ... inflammatory drug, pranoprofen was later developed into eye ... trade name of pranopulin for the treatment of ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ) ... on China,s Tobramycin Market, 2010-2019" report to their ... eye drop and ointment are the most common prescription ... caused by eye infection. Currently, dozens of enterprises in ... tobramycin, among which the Top 5 are s.a. Alcon- ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... NEW YORK, Sept. 5, 2011 Reportlinker.com announces ... in its catalogue: U.S. Market ... http://www.reportlinker.com/p0610531/US-Market-for-Emergency-Room-Equipment-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging In 2010, the ... at over $960 million. The U.S. market for ...
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... Baird,s 2011 Health Care Conference Onyx ... September 7, 2011 at 11:30 a.m. Eastern Time (8:30 a.m. ... 2011 Subsequently, Onyx will present at the Stifel Nicolaus ...
Cached Medicine Technology:U.S. Market for Emergency Room Equipment 2011 2U.S. Market for Emergency Room Equipment 2011 3U.S. Market for Emergency Room Equipment 2011 4U.S. Market for Emergency Room Equipment 2011 5U.S. Market for Emergency Room Equipment 2011 6U.S. Market for Emergency Room Equipment 2011 7
(Date:8/31/2015)... SC (PRWEB) , ... August 31, 2015 , ... GenHart ... making it their business to help small businesses operate as efficiently and cost effectively ... They've already made an impact in their first year of operation – and the ...
(Date:8/30/2015)... ... August 31, 2015 , ... The acknowledgement from Caribbean Journal comes after ... in 2015. The island of Providenciales itself received a TripAdvisor Traveller's Choice Award ... Grace Bay is offering a special promotion for newlyweds and honeymooners to celebrate this ...
(Date:8/30/2015)... ... August 31, 2015 , ... This month, top ... to help assisted living facilities and nursing homes protect their residents from neglect ... to security experts at the company, security systems don’t just protect; they also ...
(Date:8/30/2015)... ... 30, 2015 , ... InHealth Media ( http://www.inhealthmedia.com ) announced ... Director for InHealth Media. Mr. Spector comes with a wide array of ... on-air television, producing shows, on air-radio and media relations. , Brian joins ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... devices for the treatment of prostate cancer, has announced the roll-out of its ... the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in ...
Breaking Medicine News(10 mins):Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 2Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 3Health News:Grace Bay Beach Named a Top Beach Destination for Weddings 2Health News:Total Security Announces Security Systems Tips for New York Assisted Living Facilities and Nursing Homes 2Health News:Total Security Announces Security Systems Tips for New York Assisted Living Facilities and Nursing Homes 3Health News:InHealth Media Appoints New Global Communications Director 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2
... CHERRY HILL, N.J., Aug. 25 Nuvilex, Inc. (OTC Bulletin ... on September 1, 2009. Additionally, regional shareholder meetings will be held ... and Los Angeles on September 18th. Regional shareholder meeting times and ... , "We are very aware of our shareholders, ...
... , , , IRVINE, ... the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion ... by U.S. News & World Report as one of ,America,s ... SET pulse oximetry technology. , , ...
... DALLAS Aug. 25, 2009 Minorities have poorer results ... used to remove plaque from inside the carotid artery, according ... author of the study in the journal Stroke. ... July issue of the journal, found that higher rates of ...
... T. Chu, MD, PhD, associate professor at the University ... professor, Massachusetts Institute of Technology, received the 2009 Julie ... The Ellison Medical Foundation, the grants provide funding of ... in advancing understanding of basic aging and its impact ...
... , , ... Iowa has agreed to pay the United States $4.5 million to resolve ... announced today. , , ... claims to Medicare by having financial relationships with five physicians that violated ...
... ... MyClyns Product, the New Personal Germ Protection Spray , ... Mount Kisco, NY (PRWEB) August 25, 2009 -- ... media agency specializing in national brand OTC health and beauty products, recently signed an ...
Cached Medicine News:Health News:Nuvilex to Issue Positive Shareholder Newsletter 2Health News:Nuvilex to Issue Positive Shareholder Newsletter 3Health News:Nuvilex to Issue Positive Shareholder Newsletter 4Health News:Nuvilex to Issue Positive Shareholder Newsletter 5Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 2Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 3Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 4Health News:Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology 5Health News:Minorities have poorer results, higher rates of inappropriate surgery to prevent stroke 2Health News:Ellison Medical Foundation awards more than $1 million to mid-career scientists 2Health News:Covenant Medical Center to Pay U.S. $4.5 Million to Resolve False Claims Act Allegations 2Health News:Robin Leedy & Associates Wins Social Media Program For Union Springs Pharmaceuticals 2
... Sarmiento-style PTB tibial orthosis for fractures, ... closed-cell foam at bony prominences for ... 3 modular footpiece/shoe insert systems offers ... Velcro® design fits especially well in ...
Philadelphia™ Collar - Plastazote® with plastic anterior and posterior reinforcements. Hook-and-pile closure straps. Chin cradle reduces rotation. Occipital and mandibular pieces may be int...
... The Escort hip abduction brace is a lightweight ... joint technology, the Genesis Joint. The Escort ... easy to don and doff. Superior comfort ... this brace. , ,The Escort Hip ...
... Newport® Hip Management Systems are designed and ... orthosis for your patients. Innovative new options ... is built on the most successful patented ... the adjustable clamping disk design and the ...
Medicine Products: